Literature DB >> 13106703

Observations on brucellosis due to Brucella melitensis.

W W SPINK.   

Abstract

A special study was made of the problem of brucellosis due to Brucella melitensis in visits to Mexico City in 1948, to the FAO/WHO Brucellosis Centres at Montpellier (France), Florence (Italy), and Rijeka (Yugoslavia) in 1951, and to Spain in 1952. Br. melitensis infection in human beings causes more severe illness than Br. abortus infection. It develops primarily in rural communities living in close contact with goats and sheep; cattle and swine may also harbour the infection.In diagnosis, the agglutination test has proved the most satisfactory procedure; testing would be more uniformly reliable if a single antigen were used. Lack of funds and technical assistance have in many instances limited the bacteriological studies upon which a more definitive diagnosis of brucellosis depends.Antibiotics, Brucella vaccines, and colloidal preparations of gold and silver-used separately and in combination-have proved of varying therapeutic value, although response to antibiotics is less favourable than in cases of Br. abortus infection.While the drastic measures-involving the slaughter of about 10,000 sheep-taken in Slovenia, Yugoslavia, in the late 1940's, against an outbreak of brucellosis, is an inspiring example of how the disease can be eradicated, the removal of all diseased animals is rarely feasible economically. It is hoped that future research will reveal a practicable alternative in the immunization of sheep and goats against the disease.

Entities:  

Keywords:  BRUCELLOSIS

Mesh:

Substances:

Year:  1953        PMID: 13106703      PMCID: PMC2542127     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  9 in total

1.  Correlation of a rapid slide-agglutination test (Castaneda) with a tube-agglutination test in screening suspected cases of human brucellosis.

Authors:  W W SPINK; D ANDERSON
Journal:  J Lab Clin Med       Date:  1952-10

2.  An epidemiologic study of brucellosis in Minnesota.

Authors:  R L MAGOFFIN; P KABLER
Journal:  Public Health Rep       Date:  1949-08-19       Impact factor: 2.792

3.  Aureomycin therapy in human brucellosis due to Brucella melitensis.

Authors:  W W SPINK; A I BRAUDE
Journal:  J Am Med Assoc       Date:  1948-12-18

4.  Studies in the pathology and pathogenesis of experimental brucellosis. I. A comparison of the pathogenicity of Brucella abortus, Brucella melitensis, and Brucella suis for guinea pigs.

Authors:  A I BRAUDE
Journal:  J Infect Dis       Date:  1951 Jul-Aug       Impact factor: 5.226

5.  [Epidemiology of brucellosis in Argentina; brucellosis in the east and west].

Authors:  E A MOLINELLI; E M FERNANDEZ ITHURRAT; D ITHURRALDE; G BASSO; S MIYARA; A SPERONI; G PANDOLFO
Journal:  Prensa Med Argent       Date:  1951-04-20

6.  The protection of intracellular brucella against streptomycin alone and in combination with other antibiotics.

Authors:  R L MAGOFFIN; W W SPINK
Journal:  J Lab Clin Med       Date:  1951-06

7.  Follow-up study of therapy in forty-eight culturally proved cases of brucellosis; streptomycin and sulfadiazine, aureomycin, and chloramphenicol (chloromycetin).

Authors:  W W SPINK; W H HALL; R MAGOFFIN
Journal:  AMA Arch Intern Med       Date:  1951-10

8.  The influence of cortisone and adrenocorticotrophic hormone on brucellosis. II. Adrenocorticotrophic hormone (ACTH) in acute and chronic human brucellosis.

Authors:  W W SPINK; W H HALL
Journal:  J Clin Invest       Date:  1952-11       Impact factor: 14.808

9.  The protection of intracellular brucella against therapeutic agents and the bactericidal action of serum.

Authors:  J M SHAFFER; C J KUCERA; W W SPINK
Journal:  J Exp Med       Date:  1953-01       Impact factor: 14.307

  9 in total
  1 in total

1.  Experimental studies on the significance of endotoxin in the pathogenesis of brucellosis.

Authors:  W W SPINK; D ANDERSON
Journal:  J Clin Invest       Date:  1954-04       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.